On Friday, Shares of Amicus Therapeutics, Inc (NASDAQ:FOLD), gained 10.33% to $7.58. 5,152,033 shares of the company were exchanged.
The stock is down -7.9% in this year through last close, and the beta ratio has a value of 2.02. The stock, as of recent close, has shown weekly upbeat performance of 18.62% which was maintained at -58.26% in 1-month period.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Shares of Celgene Corporation (NASDAQ:CELG), declined -0.50% to $117.38, during its last trading session.
In the last trading session, the stock moved on high/low volume, trading at a volume of 5,054,839 shares as compared to its average daily volume of 6.19 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 0.81% which was maintained at -5.32% in 1-month period.
Celgene Corporation (Celgene), together with its auxiliaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products comprise REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, counting intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
At the end of Friday’s trade, Shares of Biocept Inc (NASDAQ:BIOC), inclined 1.23% to $2.47.
It traded in a range of $2.35 and $2.48, exchanging hands with 223,276 shares.
The stock is up 3.53% in this year through last close. The stock, as of recent close, has shown weekly upbeat performance of 12.27% which was maintained at 11.26% in 1-month period.
Biocept, Inc. is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), tests utilizing a standard blood sample. Its marketed tests are OncoCEE-BR for breast cancer CTC enumeration and analysis, OncoCEE-GA for gastric cancer CTC enumeration and analysis and OncoCEE-LU for non-small cell lung cancer, or NSCLC, CTC enumeration and analysis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
